Shopping Cart
- Remove All
- Your shopping cart is currently empty
CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | 30 € | In Stock | |
10 mg | 49 € | In Stock | |
25 mg | 110 € | In Stock | |
50 mg | 188 € | In Stock | |
100 mg | 302 € | In Stock | |
200 mg | 449 € | In Stock | |
1 mL x 10 mM (in DMSO) | 41 € | In Stock |
Description | CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM). |
In vitro | CCG-100602 blocks the expression of MRTF-A/SRF-activated genes. CCG-100602 (3-30?μM) decreases the number of adherent hASC cells[1]. |
Molecular Weight | 478.82 |
Formula | C21H17ClF6N2O2 |
Cas No. | 1207113-88-9 |
Smiles | FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CCCC(C1)C(=O)Nc1ccc(Cl)cc1 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (208.85 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.